HopeStage
Back to overview

Schizophrenia studies

Topics
More filters

Schizophrenia

Schizophrenia can affect how a person perceives reality, thinks and feels, sometimes involving hearing voices or holding unusual beliefs.

4505studies shown
Showing 2,905-2,916 of 4,505
Drug study icon
CompletedNCT02477670

Efficacy, Safety, and Tolerability of AVP-786 for Residual Schizophrenia

What is this study about?

This study evaluated the safety and effectiveness of AVP-786 for people with schizophrenia.

This study has finished and is no longer accepting participants.

Multiple locations, including Cerritos
SchizophreniaMedication studyAges 18–60
Countries
United States
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc. (Pharmaceutical company)
Behavioral study icon
TerminatedNCT01817387

Enhancing Motivation in Recent Onset Schizophrenia

Official study title

Developing an Intervention Strategy to Enhance Motivation in Recent Onset Schizophrenia

This study ended early.

In San Francisco
SchizophreniaBehavioural studyAges 14–30
Countries
United States
Sponsor
University of California, San Francisco
Drug study icon
CompletedNCT02146547

European Long-acting Antipsychotics in Schizophrenia study

Official study title

European Long-acting Antipsychotics in Schizophrenia Trial

This study has finished and is no longer accepting participants.

Multiple locations, including Innsbruck
SchizophreniaMedication studyAges 18+
Countries
United Kingdom, Belgium, Austria, + 13 others
Sponsor
UMC Utrecht
Drug study icon
CompletedNCT04572685

Evaluate the PK of LY03010 Process 1 and Process 2 Drug Product vs INVEGA SUSTENNA After Intramuscular Injection for schizophrenia

Official study title

A Randomized, Open-Label, Parallel, Single-Dose Study to Evaluate the Pharmacokinetic Characteristics of LY03010 Process 1 and Process 2 Drug Product Versus INVEGA SUSTENNA After Intramuscular Injection in Schizophrenia Patients

This study has finished and is no longer accepting participants.

In Berlin
SchizophreniaMedication studyAges 18–65
Countries
United States
Sponsor
Luye Pharma Group Ltd.
Behavioral study icon
CompletedNCT03338179

Evaluation of Metamemory in people with Schizophrenia

Official study title

Evaluation of Metamemory in Patients With Schizophrenia

This study has finished and is no longer accepting participants.

In Clermont-Ferrand
SchizophreniaBehavioural studyAges 18+
Countries
France
Sponsor
University Hospital, Clermont-Ferrand

Registry coverage

We gather information about mental health clinical trials from the public registries we index. Coverage is still expanding, so some studies may not appear yet.